TransMedics Group, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request refers to 2022 Q4, this filing reports annual results; the supplied text does not provide standalone fourth-quarter financial results.
Business context
TransMedics develops and commercializes its Organ Care System (OCS), a portable warm-perfusion platform for heart, lung and liver transplants, and its U.S. National OCS Program (NOP), which provides organ retrieval and management services. Revenue is primarily from single-use organ-specific disposable sets and NOP services. All three OCS products had FDA premarket approval; the company was expanding NOP and commercial adoption.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Total revenue | $93.5 million | $30.3 million |
| Net product revenue | $79.2 million | $29.7 million |
| Service revenue | $14.2 million | $0.6 million |
| Gross profit | $65.3 million | $21.2 million |
| Operating loss | $(31.4) million | $(39.4) million |
| Net loss | $(36.2) million | $(44.2) million |
| Cash used in operating activities | $(45.8) million | $(28.9) million |
- Revenue increased 208.8% year over year. Gross margin was approximately 69.8% overall; product gross margin was 79% versus 70% in 2021, while service gross margin was 21%.
- Research, development and clinical-trial expense was $26.8 million; selling, general and administrative expense was $69.9 million. Total operating expenses increased to $96.7 million from $60.6 million.
- At year-end, cash and cash equivalents were $201.2 million, current assets $252.3 million, current liabilities $23.7 million, and stockholders’ equity $187.4 million. Inventory was $20.6 million and accounts receivable $27.6 million.
- Long-term debt had $60.0 million principal outstanding under the CIBC facility, due July 2027; the balance-sheet carrying value was $58.7 million. The company reported compliance with covenants at year-end. The facility is secured by substantially all company and guarantor assets and has variable-rate interest.
- Cash increased by $175.6 million during the year, primarily reflecting $139.9 million net proceeds from an August public offering and $58.5 million net debt issuance proceeds. Shares outstanding increased to 32.1 million from 27.8 million at year-end 2021.
Material changes versus FY 2021
- U.S. revenue rose $62.2 million to $84.0 million, led by liver and heart disposable-set sales and NOP expansion. U.S. lung revenue declined $1.9 million. Non-U.S. revenue increased $1.0 million to $9.4 million.
- NOP-related customers represented approximately 89% of U.S. revenue. Service revenue rose sharply following the program’s late-2021 launch, but service costs also increased substantially; service gross margin was 21%.
- SG&A rose $31.6 million, mainly from personnel and stock-based compensation, NOP logistics and expansion costs, and higher conference activity. R&D and clinical-trial expense rose $4.5 million, principally from next-generation product and research activity.
- Operating cash use increased $17.0 million, including a $21.7 million increase in accounts receivable and an $8.0 million increase in inventory. Management cited business growth and invoice/payment timing as drivers of working-capital movements.
- The company refinanced its former OrbiMed debt with a $60 million CIBC facility in July 2022 and raised equity in an August public offering.
Outlook, risks and unusual items
- Management expects continued investment in commercial growth, NOP expansion, manufacturing and sterilization capacity, and next-generation OCS development. It expects ongoing losses for the foreseeable future and did not provide a numerical revenue or earnings forecast in the supplied filing text.
- Management stated that year-end cash was expected to fund operating expenses, capital expenditures and debt service for at least 12 months after the filing date, based on assumptions that may prove incorrect. Additional financing may be needed.
- Key risks include continued losses and cash burn; reliance on OCS adoption and reimbursement; NOP staffing, logistics and aircraft availability; scaling a single Andover manufacturing site; reliance on single- or sole-source suppliers and third-party sterilizers; regulatory approvals and post-approval studies; and customer concentration. Mayo Clinic Hospital–Phoenix accounted for 14% of 2022 revenue.
- International OCS reimbursement remained limited; the company was seeking longer-term reimbursement in several jurisdictions. MDR recertifications were obtained for specified OCS products, while approval for the OCS Liver combined with solution additives was still pending.
- Gross profit included a favorable $1.4 million effect from revisions to certain clinical-trial accrual estimates. The debt refinancing resulted in a $0.6 million loss on extinguishment. Foreign-currency transaction losses were $1.3 million.
- No material legal proceedings were reported. The company paid no dividends and did not anticipate cash dividends in the foreseeable future. The auditor gave unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether rapid revenue growth continues and how much is attributable to OCS disposable products versus NOP services.
- NOP unit economics, service margins, transportation costs and the program’s ability to expand without eroding profitability.
- Receivables collection, inventory growth and operating cash burn relative to reported revenue growth.
- Manufacturing and sterilization capacity, supplier concentration, and progress on the expanded facility and international certifications.
- Reimbursement developments, completion of FDA post-approval studies, and continued compliance with CIBC financial covenants.